CD36 transcription in monocyte/macrophages, adipocytes, and myocytes is tightly regulated by various cellular stimuli, including cytokines, lipids and lipoproteins, reactive oxygen species, and differentiation and adhesion events. 10 The expression is also regulated post-transcriptionally. Accelerated atherosclerosis in diabetics has been linked to increased translation of macrophage CD36 transcripts under high-glucose conditions. 11 Despite the biological importance of CD36 in angiogenesis, little is known about how endothelial cell (EC)-specific CD36 transcription is regulated or how that might relate to EC heterogeneity and function. In retinal microvascular endothelial cells (MVECs), CD36 transcription is upregulated in response to hypoxia via HIF-1 transcription factor. 12 The antiangiogenic pathway triggered by HIF-1 signaling counteracts hypoxia-driven proangiogenic Objective-CD36 is a scavenger and antiangiogenic receptor that is important in atherothrombotic diseases, diabetes mellitus, cancer, and obesity. Lysophosphatidic acid, a phospholipid signaling mediator, abolishes endothelial cell responses to antiangiogenic proteins containing thrombospondin type 1 homology domains by downregulating endothelial CD36 transcription via protein kinase D1 (PKD-1) signaling. We aimed to understand mechanisms by which lysophosphatidic acid-mediated angiogenic signaling is integrated to regulate CD36 transcription and endothelial cell function via a nuclear transcriptional complex. Approach and Results-Microvascular endothelial cells expressing CD36 were used for studying angiogenic signaling and CD36 transcription. Gene transfection and transduction, RT-qPCR, avidin-biotin-conjugated DNA-binding assay, chromatin immunoprecipitation assay, co-immunoprecipitation, proximal ligation assay, and immunofluorescence microscopy showed that lysophosphatidic acid-mediated CD36 transcriptional repression involved PKD-1 signaling mediated formation of forkhead box protein O1-histone deacetylase 7 complex in the nucleus. Unexpectedly, turning off CD36 transcription initiated reprogramming microvascular endothelial cells to express ephrin B2, a critical molecular signature involved in angiogenesis and arteriogenesis. Spheroid-based angiogenesis and in vivo Matrigel angiogenesis assays indicated that angiogenic branching morphogenesis and in vivo angiogenesis were dependent on PKD-1 signaling.
A dynamic balance between pro-and antiangiogenic signals determines neovessel formation during physiological and pathological conditions. Broadly and constitutively expressed in microvascular beds, CD36 functions as a receptor that can initiate an antiangiogenic response by interaction with thrombospondin-1 and related proteins containing thrombospondin type 1 repeat (TSR) domains. [1] [2] [3] [4] TSR binding to CD36 provides a switch that blunts vascular endothelial growth factor receptor signals 5, 6 and converts growth factor-mediated proangiogenic responses into antiangiogenic, proapoptotic responses. [1] [2] [3] [4] [6] [7] [8] [9] Diminishing CD36 expression, for example in tumor vasculature, may tip the balance in favor of proangiogenic responses under certain pathological circumstances. pathways, providing a homeostatic brake to prevent pathological neovascularization. Recently, we showed that lysophosphatidic acid (LPA), a phospholipid signaling mediator and angiogenic factor, [13] [14] [15] [16] [17] [18] [19] led to long-term CD36 transcriptional repression via protein kinase D1 (PKD-1) signaling in MVECs to promote angiogenesis. 7 The precise mechanisms, however, by which LPA-mediated PKD-1 signaling regulates CD36 transcription and functions remain largely unknown.
PKD-1 is a serine/threonine protein kinase that is classified as a member of the calcium/calmodulin-dependent protein kinase family. PKD-1-initiated signaling is essential for angiogenesis, inflammatory responses, cardiac hypertrophy, and tumor progression, and related to its functions in regulating cell proliferation and death, migration, and differentiation. 7, [20] [21] [22] [23] [24] [25] [26] [27] We have hypothesized that PKD-1 signaling triggered by LPA receptors initiates assembly of a nuclear transcriptional complex, which suppresses CD36 transcription and thereby turns off the antiangiogenic switch. We found that forkhead box protein O1 (FoxO1) controls basal MVEC CD36 transcription and that PKD-1 signaling induces recruitment of a corepressor, nuclear receptor corepressor 1, and a specific histone deacetylase (HDAC), HDAC7, to the FoxO1 nuclear complex, resulting in CD36 transcriptional repression. Intriguingly and unexpectedly, downregulation of CD36 transcription was associated with reprogramming of MVEC transcription toward proangiogenic and arteriogenic gene expression, which is partially dependent on CD36 expression. Furthermore, the activation of this signaling pathway in the tumor vasculature of mice could be associated with CD36 deficiency and proangiogenic and proarteriogenic responses in the tumor microenvironment. Our study suggests that there is a plasticity in EC differentiation and postnatal angiogenesis, which is regulated by the LPA/PKD-1-FoxO1-CD36 signaling pathway. Targeting this pathway could provide a novel therapeutic strategy in ischemic heart and vascular diseases, cancer, and other disorders, such as diabetes mellitus and obesity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CD36 Transcription in ECs Is Regulated by HDAC7
HMVECs transfected with a luciferase reporter plasmid (pGL3-CD36-luc) encoding a 3519 bp sequence of the CD36 gene immediately proximal to the transcriptional start site 12 showed significant basal luciferase activity ( Figure 1A) compared with cells transfected with the control pGL3 plasmid. Activity was decreased by >80% after LPA exposure for 24 hours (P<0.01). Moreover, CD36 transcriptional repression was long lasting; removal of LPA from MVEC cultures after 24 hours followed by reconstitution in complete media for 48 hours did not restore the CD36 transcription ( Figure 1B ). There was also a significant downregulation of CD36 in primary human cardiac MVEC (HMVEC-C), which was not seen in cells treated with a pharmacological inhibitor of the G-protein-coupled LPA receptors LPA 1 and LPA 3 ( Figure 1C ). To determine whether this long-lasting effect was associated with chromatin remodeling, we assessed CD36 promoterspecific histone acetylation status by chromatin immunoprecipitation analyses and found that nucleosome histone H3K9 enrichment in the CD36 promoter was reduced in response to LPA for 24 hours ( Figure 1D ), suggesting that CD36 transcriptional repression by LPA may be regulated by HDAC.
Class IIa HDACs including HDAC5 and HDAC7 are signal-dependent modulators of transcription 28 and previous studies indicated that HDAC5 29 and HDAC7 30 play roles in PKD signaling and gene transcription that regulates EC functions. 30, 31 We hypothesized that LPA suppression of CD36 transcription was via either one or both of these HDACs. To test this hypothesis, we pretreated HMVECs with class IIa HDAC inhibitors, suberoylanilide hydroxamic acid, or trichostatin A, and then exposed them to LPA. Both inhibitors abolished LPA-mediated downregulation of CD36 protein expression ( Figure 1E ). By using immunofluorescence microscopy and biochemical cell fractionation, we found that LPA exposure increased the nuclear accumulation of HDAC7 but not HDAC5 (Figure 2A ).
To define the role of specific HDACs in LPA-mediated CD36 transcriptional repression, we knocked down HDAC7 expression in human MVECs transfected with pGL3-CD36luc by using a specific shRNA ( Figure 2B , top) and showed that LPA-inhibited CD36 promoter activity was partially attenuated (Figure 2B, bottom; P<0.01). Moreover, LPA-mediated CD36 mRNA downregulation was blocked by transfection with shRNA plasmids targeting HDAC7 ( Figure 2C ). Knockdown of HDAC5 had no effect in these assays (data not shown).
Transcription Factor FoxO1 Is Required for Constitutive CD36 Transcription in MVECs
We next sought to identify transcription factors responsible for EC CD36 transcription. The analysis of the CD36 gene promoter region revealed 3 putative FoxO-responsive elements (FHRE) located between −3500 to −250 bp relative to transcription start site ( Figure 3A , top). FoxO1, a member of Forkhead transcription factor family, is known to be important in vascular development and postnatal angiogenesis. 32, 33 We deleted proximal promoter sequences containing FHRE at 258 bp relative to transcriptional start site in the pGL3-CD36-luc plasmid. The deletion of this regulatory element significantly reduced basal promoter activity in HMVECs ( Figure 3A , bottom). Similar results were seen when this FHRE was subjected to site-directed mutagenesis ( Figure 3A, regulatory regions of the CD36 gene ( Figure 3B , top). Whereas the transcription factor the nuclear receptor subfamily 4 group A member 1 did not bind CD36 promoter sequences in these experiments, demonstrating specificity. To investigate mechanisms by which FoxO1 might play a role in LPA-mediated CD36 repression, ChIP analyses were performed to determine whether the interaction between FoxO1 and the CD36 gene was altered in response to LPA. Unexpectedly, no significant change was seen ( Figure 3B , bottom). However, using an alternative avidin−biotin conjugated DNA and protein-binding assay we found that LPA induced increased FoxO1 interaction with the CD36 proximal promoter but not distal promoters in vitro ( Figure 3C ). This is consistent with the data ( Figure 3A) showing that deletion or mutation in the proximal FHRE abrogated basal promoter activity. Further analyses revealed that deletions in the distal promoter removing sequences from −2799 to −396 did not have a significant impact on promoter activity in MVECs ( Figure 3D ). These results suggest other mechanisms are involved in the regulation of FoxO1 transcriptional activity by LPA.
Having shown that the proximal FHRE is essential for basal CD36 promoter activity in HMVECs and that LPA actually increased FoxO1 interaction with the promoter, we reasoned that the inhibitory effect of LPA was because of recruitment of a transcriptional repressor. Indeed LPA treatment of HMVECs induced interaction of the corepressor nuclear receptor corepressor 1 with FoxO1. Although this interaction was attenuated by pharmacological inhibition of PKD-1 ( Figure 3E Lysophosphatidic acid (LPA)-mediated sustained CD36 transcriptional repression may be associated with histone deacetylase activity in endothelial cells. A, LPA exposure suppresses CD36 promoter activity. Primary human microvascular endothelial cells (HMVECs) were transfected with reporter constructs containing the CD36 proximal promoter fused to the pGL3-basic (pCD36-luc) for 24 hours with cotransfection of pRL Renilla luciferase for normalization. The cells were then exposed to LPA for 24 hours before measurement of luciferase activity with Dual-Luciferase Reporter Assay System. Promoter activity was expressed as the fold-change in relative luciferase activity compared with pGL3.2 basic control (mean±SE of 3 independent experiments). B, LPA mediates sustained CD36 mRNA downregulation. Primary HMVECs were exposed to LPA (10 μmol/L) for 24 hours, and then LPA was removed and replaced with complete media for 48 hours. The mRNA level was assayed with quantitative real-time RT-PCR. Triplicate experiments were performed (P<0.01). C, LPA signaling significantly reduces CD36 mRNA expression in cardiac microvascular endothelial cells (HMVEC-C). Primary HMVEC-Cs (passage 3) were exposed to LPA (10 μmol/L) for 24 hours or pretreated with LPA receptor1,3 antagonist Ki16425 (2 μmol/L) for 30 minutes followed by LPA (10 μmol/L) for 24 hours. Total RNA was obtained for quantitative real-time RT-PCR. D, ChIP analyses targeting the CD36 proximal promoter in LPA-treated (10 μmol/L, 24 hours) HMVECs using antibodies against AcH3 (K9). Input shows DNA isolated from the lysate before immunoprecipitation (10% of the total chromatin was used for the PCR reactions). Lane labeled IgG is ChIP performed with a nonimmune IgG. E, CD36 expression in primary HMVECs treated with LPA and histone deacetylase inhibitors suberanilohydroxamic acid (SAHA) or trichostatin (TSA). The HMVECs were pre-exposed to 500 nmol/L of SAHA or 500 ng/mL of TSA for 30 minutes followed with 10 μmol/L of LPA for 24 hours. Cell lysates were subjected to Western blots for CD36 protein expression (left). Densitometry was performed and relative expression levels calculated for triplicate experiments (right).
kinase that we showed was downstream of LPA signaling in the CD36 transcriptional repression pathway. 7
LPA/PKD-1 Signaling Mediates FoxO1-HDAC7 Interaction
To explore potential mechanisms by which LPA/PKD-1 signaling contributes to endothelial CD36 transcription, we generated lentiviral vectors encoding green fluorescence protein, wild-type PKD-1 or constitutively active PKD (PKD-CA) fused to green fluorescence protein ( Figure 4A ), 34 using both tetracycline inducible and constitutive systems. Tumorassociated endothelial cells that express abundant CD36 were transduced by the inducible PKD-CA lentivirus and then exposed to doxycycline. The doxycycline treated cells showed downregulated CD36 protein expression ( Figure 4A ) to levels similar to that seen in HMVECs exposed to LPA. Because specialized roles of PKD-1 may depend on both its localization and substrate proximity, 27 we examined PKD-1 intracellular localization by fluorescence microscopy ( Figure 4B , left). LPA exposure increased nuclear PKD-1 expression, and the phosphorylated PKD-1 was also increased in the nucleus in response to LPA treatment by fluorescence confocal laser scanning microscopy ( Figure 4B , right). To confirm the microscopy data, we performed cell fractionation to isolate nuclear components. Western blots of cell fractions showed that LPA increased nuclear accumulation of PKD-1 ( Figure 4C ). Similarly, LPA exposure increased nuclear FoxO1 levels in HMVECs as determined by Western blots and immunofluorescence microscopy ( Figure 4D ).
Having shown that PKD-1 and its substrate HDAC7 20,35 as well as FoxO1 accumulate in the MVEC nuclei in response to LPA, we hypothesized that PKD-1 mediates formation of a nuclear signaling complex to regulate CD36 transcription. HMVECs were thus transfected with Flag-tagged FoxO1 to assess FoxO1-HDAC7 interactions in response to LPA. Co-immunoprecipitation experiments showed that FoxO1 interacted with endogenous HDAC7 at a basal level and that LPA exposure enhanced the interaction ( Figure 4E ). Furthermore, inducing expression of either wild-type PKD-1 or PKD-CA by doxycycline promoted FoxO1-HDAC7 interactions, but PKD-CA promoted interaction to a greater extent ( Figure 4F ). To determine whether PKD-1 is essential for this interaction, we knocked down PKD-1 expression in the cells with RNAi plasmids. FoxO1-HDAC7 interactions in response to LPA were significantly attenuated with PKD-1 knockdown ( Figure 4G ). To assess interactions of endogenous FoxO1 and HDAC7 in HMVEC-C, we utilized a fluorescence-based immunologic cross-linking assay (proximity ligation assay) that uses antibodies to the 2 proteins derived from different animal species and detects proteins in close proximity (<40 nm) microscopically as bright red fluorescent dots. As seen in Figure 4H , multiple bright dots were seen in cell nuclei after LPA treatment, but not in the control untreated cells ( Figure 4I , P<0.01). As an additional control, no signal was detected using antibodies to FoxO1 and HDAC5 ( Figure Microvascular endothelial cells were exposed to LPA (10 μmol/L) for 24 hours and then incubated with antibodies to HDAC5 or HADC7 followed by Alexa fluor conjugated secondary antibodies. Cells were costained with DAPI to mark nuclei. In some studies, cells were fractionated and the nuclear fractions isolated and subjected to Western blots for HDAC5 or HDAC7 expression. Representative results are shown from triplicate experiments. B, Knocking down endogenous HDAC7 attenuates LPA-mediated CD36 transcriptional repression in human microvascular endothelial cells (HMVECs). Western blots showed that HDAC 7 shRNA plasmids transfection effectively reduced the endogenous HDAC7 expression (top). Cells transfected with HDAC7 shRNA plasmids or scrambled control were cotransfected with pGL3-CD36-luc and Renilla plasmids for 48 hours. The cells were exposed to LPA (10 μmol/L) or vehicle control for 24 hours and luciferase activity measured as in Figure 1A (P<0.01). C, HMVECs were transfected with a pool of HDAC7 shRNA plasmids for 28 hours, and the cells were exposed to LPA (10 μmol/L) for 18 hours. The cells were harvested and total RNA was isolated for RT-PCR for CD36 mRNA expression. The image shows a representative gel from triplicate experiments. . Human microvascular endothelial cells (HMVECs) were exposed to LPA (10 μmol/L) for 24 hours and subjected to Chromatin immunoprecipitation analyses. Nur77 (nuclear receptor subfamily 4 group A member 1) is used as a control. Representative results are shown in triplicate experiments. C, LPA increases the interactions of FoxO1 FHRE with the CD36 proximal promoter. On the basis of putative-binding sites for FoxO1 at CD36 promoter, biotin-labeled probes targeting FHRE respectively at proximal, distal promoter, or irrelevant site were designed for detecting FoxO1 interaction with FHREs. HMVECs were exposed to LPA (5 μmol/L) for 24 hours, and the nuclear components were isolated and subjected to an avidin-biotin conjugated DNA-binding assay. D, Distal promoter deletion does not alter CD36 promoter activity. The CD36 promoter variants in the luciferase reporter system were prepared as shown in left and the basal CD36 promoter activity with various deletion mutations were assayed in the HMVECs as in Figure 1A (right). E, (Continued ) the online-only Data Supplement). Co-immunoprecipitation confirmed the increased interaction between endogenous HDAC7 and FoxO1 ( Figure 4J ), and this interaction was attenuated partially by treating the cells with a pharmacological PKD inhibitor ( Figure 4J ).
Regulation of Proarteriogenic and Angiogenic Responses by LPA/PKD-1 Signaling
To determine whether the repression of CD36 transcription induced by LPA/PKD-1 signaling is part of a broader program of angiogenic gene regulation, we performed a focused angiogenic gene expression array using real-time qPCR. In response to LPA exposure, the expression levels of 20 angiogenic genes were upregulated >3-fold, including EFNB2, neuropilin 1, and flt1 ( Figure IIA and IIB in the online-only Data Supplement). These data suggest that downregulation of the antiangiogenic receptor CD36 was linked to the upregulation of specific proangiogenic genes. Ephrin B2 (EFNB2) is an arterial EC marker that is important in angiogenesis and arteriogenesis. [36] [37] [38] To validate the qPCR profiling data, we showed significant increased expression of EFNB2 mRNA by qPCR and of protein by Western blots in the PKD-CA transduced HMVEC-C and mouse MVEC lines ( Figure 5A and 5B). Moreover, overexpressing PKD-CA in HMVEC-C significantly increased expression of additional proarteriogenic genes including δ-like ligand 4 and HEY2, but not neu-ropilin1 ( Figure 5C ). Overexpressing CD36 downregulated EFNB2 expression in HMVEC-C and LPA treatment significantly reversed CD36-mediated downregulation ( Figure 5D ). Intriguingly, CD36 overexpression did not significantly change δ-like ligand 4, HEY2, or neuropilin1 expression ( Figure 5E ). To show functional significance of this transcriptional program switch, we studied the impact of LPA on angiogenic differentiation in mouse heart MVECs expressing CD36. Exposure to LPA promoted endothelial sprout formation in vitro as measured in a 3-dimensional spheroid assay; the spheroids showed robust branching morphogenesis compared with the control (P<0.01, Figure 6A ), and this was partially attenuated by addition of a selective PKD inhibitor (P>0.05, Figure 6A ). Furthermore, an in vivo Matrigel assay showed that pharmacological inhibition of PKD signaling reduced the inhibitory effect of LPA on TSR/CD36-mediated antiangiogenic effects in response to VEGF in vivo ( Figure 6B Figure 6C, bottom right; P>0.05) . These data suggest the LPA signaling through PKD pathway in MVECs can affect VSMC function via secreted factors. We also examined tumor angiogenesis and relevant signaling pathways in a syngeneic tumor transplant model using Lewis Lung Carcinoma cells in wild-type and cd36 null mice. Immunofluorescence microscopy revealed extensive angiogenesis within the tumors detected with anti-VEGFR2 antibody ( Figure 6D and 6E , bottom). The angiogenic response was associated with lower levels of expression of CD36 in the neovessels compared with nearby cutaneous vessels ( Figure 6D and 6E) and with expression of phospho-PKD-1, EFNB2, and α-smooth muscle actin in the tumor vasculature ( Figure 6E-6G ). There was no significant difference in the number of α-smooth muscle actin expressing cells in tumor vessels in wild-type and cd36 null mice ( Figure 6G , right, P>0.05).
Discussion
CD36 is an important angiostatic receptor on MVECs that interacts with TSP-1 and other antiangiogenic proteins containing TSR domains [1] [2] [3] [4] to modulate VEGF signaling and promote EC apoptosis. Our previous work demonstrated that LPA promotes angiogenesis in the presence of antiangiogenic TSRcontaining proteins by downregulating CD36 gene transcription via a PKD-1 pathway. 7 In this study, we made the novel observations that the transcription factor FoxO1 is required for constitutive CD36 expression in MVECs and, as shown in the model in Figure 7 , that LPA-mediated PKD-1 activation and nuclear translocation results in recruitment of the class II HDAC HDAC7 to the CD36 promoter, driving formation of an HDAC7/nuclear receptor corepressor 1/FoxO1 nuclear complex and subsequently triggering CD36 transcriptional repression. Furthermore, turning off CD36 transcription was associated with transcriptional reprogramming that upregulated expression of arterial genes, including EFNB2. On a functional level, our data suggest that activating this pathway in vivo may promote microvascular remodeling and functional stability ( Figure 6 ), and in murine tumor model systems, the absence of CD36 was associated with increased expression of the arterial marker in the tumor microvasculature.
These results also support the concept that terminally differentiated MVECs are developmentally plastic, and in the setting of specific environmental cues can be reprogrammed [39] [40] [41] [42] toward an arteriogenic phenotype that includes change in expression of surface proteins and secretion of factor(s) that support VSMC proliferation and migration. LPA is likely to be an important such cue because it is often generated in angiogenic microenvironments associated with inflammation, ischemia, platelet activation, cancer, and obesity. Consistent Figure 3 Continued. Protein kinase D1 (PKD-1) signaling regulates recruitment of corepressor nuclear receptor corepressor 1 (NCoR1) to FoxO1 complex in response to LPA. HMVECs were exposed to LPA (10 μmol/L) for 24 hours or pre-exposed to a selective PKD inhibitor CID 755673 (25 μmol/L) for 30 minutes followed with LPA (10 μmol/L) for 24 hours before the cell lysates were collected and subjected to co-immunoprecipitation (IP). Representative result is shown. PKD-CA was established. TAECs were transduced with the vector and GFP-positive clones were selected. Clone 3 cells were grown in the presence of 1 μg/mL doxycycline for 36 hours, and cell lysates were processed and subjected to Western blots. B, PKD-1 is translocated to the nucleus in response to lysophosphatidic acid (LPA). Human microvascular endothelial cells (HMVECs) were exposed to LPA (5 μmol/L) or vehicle for 24 hours (left) or for 30 minutes (right) and incubated with anti-PKD-1 or anti-phospho-PKD-1 antibodies followed by Alexa Fluor second antibody. Images were obtained with an immunofluorescence microscopy or confocal microscopy. C, HMVECs were exposed to LPA (5 μmol/L) for 24 hours, the nuclear components were isolated and subjected to Western blots for total PKD-1, and histone 3 antibodies were used to determine nuclear protein loading. The relative PKD-1 level was determined by densitometry for triplicate experiments. D, FoxO1 level increases in the nucleus with LPA exposure. After LPA (10 μmol/L) treatment for 24 hours, ECs were subjected to immunofluorescence microscopy using anti-FoxO1 antibody (bottom). In some studies, nuclear components were isolated from the cells and subjected to Western blots for FoxO1 protein expression and relative density was calculated from triplicate experiments (top). E, LPA promotes HDAC7-FoxO1 interaction. HMVECs were transfected with FoxO1-flag for 36 hours and then exposed to LPA (5 μmol/L) for 18 hours. Lysates were immunoprecipitated with HDAC7 antibody and reprobed with anti-Flag antibody. Total cell lysate was subjected to Western blots for Flag-tag. F, Overexpressing PKD-1 increases HDAC7 interaction with FoxO1. TAECs transduced with pLVET-GFP: PKD1-WT or pLVET-GFP: PKD1-CA plasmids were cotransfected with FoxO1-Flag in the absence or presence of doxycycline (1 μg/mL) for 36 hours. Cell lysates were collected and immunoprecipitated with anti-Flag antibody, (Continued ) with previous reports, 43, 44 our results show unsaturated LPA promoted SMC entry into Matrigel plugs in vivo. Although our data suggest that LPA in the microenvironment of lung cancers may reduce MVEC CD36 expression and contribute to microvascular remodeling comparable with that seen in the cd36 null mice at the late stages of tumor development examined in these studies, we did not detect differences in VSMC investment in neovessels, as detected by anti-α-smooth muscle actin staining. Our data also suggest that CD36 transcriptional status might be more than just a marker for the loss of capillary endothelial phenotype. Forced expression of CD36 in MVECs abrogated the arteriogenic switch that may be turned on by LPA, perhaps implicating CD36 in the regulatory pathway.
PKD-1-mediated signaling has been shown to regulate cardiovascular functions, including myocardial responses to ischemia, angiogenesis, and arterial remodeling, 7, [20] [21] [22] [23] [24] 42, 45 and the transcription factor FoxO1 is well known to be involved in vascular development, postnatal angiogenesis, 32, 33 and regulation of EFNB2 expression. 46 Our study now links the PKD-1 signaling pathway initiated by specific LPA receptors to FoxO1 in MVECs and demonstrates a critical mechanistic role for nuclear accumulation of activated PKD-1 in recruiting a specific class II HDAC, HDAC7, to the FoxO1 transcriptional regulatory complex. HDAC7, which is known to be highly expressed in ECs, 45, 47 was previously shown by Chang et al 31 to be important in maintenance of vascular integrity during embryonic development via a mechanism that involves Figure 4 Continued. followed by Western blot analyses using anti-HDAC7 or anti-Flag antibody. G, PKD-1 is required for HDAC7-FoxO1 interactions. HMVECs transfected with scrambled RNAi plasmids (Scramble), or pSUPER PKD-1 RNAi and cotransfected with FoxO1 for 36 hours were treated with LPA (5 μmol/L) for 18 hours and analyzed by Co-IP for FoxO1-HDAC7 interactions as in E. Representative results are shown in the figure. H, LPA exposure promotes interaction of endogenous HDAC7 and FoxO1 in the nucleus of HMVEC-C. In response to LPA (10 μmol/L), there was a significant increase in the HDAC7-FoxO1 interaction in early passages of HMVEC-C (P3) detected as bright red dots in the cell nuclei by fluorescence microscopy using the proximity ligation assay (PLA). I, Increased relative density of red fluorescent dots in the PLA indicating HDAC7-FoxO1 interactions in HMVEC-C exposed to LPA (10 μmol/L). J, LPAinduced HDAC7-FoxO1 interaction was partially attenuated by PKD inhibitor. HMVEC-C (P3) was exposed to LPA (10 μmol/L), LPA (10 μmol/L) plus a selective PKD inhibitor CID755673 (25 μmol/L) or buffer control and the nuclei were isolated and subjected to immunoprecipitation with anti-HDAC7 followed by immunoblot with anti-FoxO1 to detect endogenous interactions. Figure 6 . Protein kinase D1 (PKD-1) signaling promotes proangiogenic and proarteriogenic responses. A, PKD-1 signaling is associated with lysophosphatidic acid (LPA)-stimulated sprouting morphogenesis in primary mouse heart endothelial cells (MHECs). MHECs were exposed to LPA and used in a 3-dimensional spheroid assay. LPA (10 μmol/L) was added to the media for 48 hours to induce branching morphogenesis, and a selective PKD inhibitor CID755673 (25 μmol/L) was added in a group with LPA treatment with vehicle as control. Branching morphogenesis was observed under fluorescence microscope and pictures were taken with a digital (Continued ) inhibition of a transcriptional activator, myocyte enhancer factor-2 (MEF-2). This interaction results in transcriptional repression of the matrix metalloproteinase-10 gene and promotes stability of the extracellular matrix. Thus these studies and our new data show that HDAC7 interacts with specific EC transcription factors (FoxO1 and MEF-2) that function in at least two pathways related to vascular development and stability. Our studies using pharmacological HDAC inhibitors or specific shRNA (Figures 1E, 2B , and 2C) also suggest that HDAC7 could be a therapeutic target to destabilize angiogenesis and modulate EC differentiation. 48 CD36 is a multifunctional transmembrane protein that on phagocytic cells serves as a scavenger receptor for endogenous danger-associated molecular patterns (eg, oxidized low density lipoproteins) and exogenous pathogen-associated molecular patterns (eg, staphylococcus lipoteichoic acid). 3 On fat, muscle, and gut epithelial cells CD36 functions as a transporter of free fatty acids. Interestingly, CD36 transcriptional regulation in MVECs is very different than in these other cell types, in which expression is regulated both positively and negatively by metabolic factors, cytokines, bacterial components, reactive oxygen species, and adhesion. 3, 10 Our studies have not revealed any response of CD36 expression in MVECs to those factors that up-regulated CD36 in phagocytic cells, fat and muscle (eg, PPARγ agonists and cytokines) or that down-regulated expression in these cells (eg, bacterial endotoxin), suggesting Figure 7 . Model showing potential mechanism by which an lysophosphatidic acid (LPA)/protein kinase D1 (PKD-1)-histone deacetylase 7 (HDAC7)-FoxO1 signaling axis regulates endothelial cell (EC) CD36 transcription and angiogenesis. LPA signaling in microvascular endothelial cell is mediated by G-protein-coupled LPA receptors 1 and 3 at the EC membrane (M), which activate PKD-1, leading to PKD-1 and HDAC7 translocation into the nucleus (N) where they interact with the transcription factor FoxO1 and the corepressor nuclear receptor corepressor 1 (NCoR1). This results in CD36 transcriptional repression and reprogramming EC to express ephrin B2, which promotes angiogenesis, arteriogenic differentiation, and microvascular remodeling. Sprouting described in B was quantified microscopically by counting sprouts per spheroid at 48 hours in response to LPA (bottom). B, LPA inhibition of thrombospondin type 1 repeat (TSR)-induced inhibition of vascular invasion is partially dependent on PKD-1 signaling. Matrigel plugs mixed with a combination of VEGF (50 ng/mL), recombinant TSR (10 nmol/L), LPA (10 μmol/L), and CID 755673 (25 μmol/L) were injected into mice and analyzed histologically after 10 days. Bar graph shows the relative angiogenic responses and vascular invasion in the Matrigel plugs (left). In addition, LPA signaling promotes vascular remodeling. Matrigel plugs mixed with a combination of VEGF (50 ng/mL) and LPA (10 μmol/L) or VEGF and LPA plus LPA receptor 1,3 antagonist Ki16426 (2 μmol/L) were, respectively, injected into mice and analyzed histologically after 10 days. Representative Masson Trichrome stained images are shown and bar graph shows vascular invasion relative to VEGF stimulation (right; P>0.05; scale bar 50 μm). Images were acquired with a Nikon Eclipse E600 microscope, and NIH Image J was used for the analysis of vascular invasion. ns indicates no significant statistical difference. C, LPA stimulates the formation of smooth muscle actin (SMA)-positive vessels. Matrigel plugs were sectioned and examined with an EVOSFL imaging system using antibodies to alpha SMA (green), and nuclei was stained with DAPI (blue), and representative images are shown, sacle bar=200 μmol/L. Images with positive SMA staining were randomly collected and the positive cells counted with NIH image J. The average cell number was calculated in each visual field and compared between VEGF and LPA plus VEGF groups (P<0.05, top and bottom) . In addition, vascular smooth muscle cells (VSMCs) were exposed to the conditioned media from HMVECs treated with LPA or LPA and PKD inhibitor, and cell proliferation was assessed by an alamarBlue Cell viability assay (lower right). Two independent experiments were performed, and the cell proliferation is represented as relative fluorescence intensity. LPA-conditioned media significantly increases VSMC proliferation (P<0.05; ns: no significant statistical difference). D, Tumors harvested from C57Bl and cd36 +/+ mice after transplantation of Lewis Lung carcinoma cells were sectioned and examined by immunofluorescence microscopy using antibodies to VEGFR2 (red) and CD36 (green). Nuclei were stained with DAPI (blue, ×100). CD36 expression in skin adjacent to the tumors and sections incubated with CD36 antibodies or nonimmune IgG are shown as positive and negative controls. Representative results are shown. E, Tumor vessels as in D were examined by immunofluorescence using antibodies to phospho-PKD-1 (white) in wild-type or the cd36 null mice, and no PKD-1 phosphorylation was shown in the skin adjacent to the tumor tissues. VEGFR-2 (red) staining was shown in the tumor tissues to visualize the angiogenic response in the cd36 null mice. Hematoxylin and eosin staining is used to show tumor tissues in both wild-type and cd36 deficiency mice (×40). Representative images are shown. F, Tumor vessels were examined by immunofluorescence using antibodies to ephrin B2 (EFNB2, magenta) in wild-type or the cd36 null mice. Representative images are shown. G, Tumor vessels were examined by immunofluorescence using antibodies to α-SMA and VEGFR2 and DAPI was used for staining the nuclei (VEGFR2 red, SMA green, and DAPI blue) in wild-type or the cd36 null mice. Images were randomly acquired with a Zeiss Axioskop Microscope with Photometrics Cool SNAP ES Camara system using Metamorph v7 software or EVO ® FL cell imaging system, and representative images are shown (left). NIH Image J was used to analyze the integrated fluorescence density (IFD) of SMA-positive cells (green) in the hypervascular areas of the tumor microenvironment. The average IFD was used to assess the relative number of SMA-positive cells in the neovessels and compared between wild-type and cd36 null mice. No significant statistical difference was found between these 2 groups (P>0.05, right). that the expression of CD36 in MVECs may have evolved for a different function; that is, as a receptor for TSR proteins and a regulator of both angiogenesis and arteriogenesis, 38 rather than as a scavenger receptor or fatty acid transporter. Further study of the precise mechanisms linking CD36 expression to EC differentiation and of the in vivo relevance of this regulatory pathway may aid in discovering novel therapeutic targets against ischemic diseases, cancer, obesity and diabetes.
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